ND-026
- Generic Name
- ND-026
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Yellow Jersey Therapeutics AG
- Target Recruit Count
- 126
- Registration Number
- NCT05859724
- Locations
- 🇺🇸
First OC Dermatology Research, Fountain Valley, California, United States
🇺🇸California Clinical Trials Medical Group (CCTMG) managed by Parexel, Glendale, California, United States
🇺🇸TCR Medical Corporation, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath